CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

Aetion, Inc.851 enrolled

Overview

The goal of this non-interventional study is to emulate the KEYNOTE-189 randomized controlled trial of pembrolizumab for the treatment of metastatic non-small cell lung cancer using real-world, electronic health record data. The main questions this study aims to answer are: 1. Do patients with metastatic non-small cell lung cancer (NSCLC) treated with pemetrexed, cisplatin/carboplatin, and pembrolizumab have improved real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) compared with patients treated with pemetrexed and cisplatin/carboplatin alone? 2. How do the results of this non-interventional study compare to those of the KEYNOTE-189 randomized controlled trial?

The Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative is a program designed to build an empirical evidence base for the use of real-world data (RWD) in clinical and regulatory decision-making. Using randomized controlled trials (RCTs) as a benchmark for causal effect estimates, a series of RCT emulations will be conducted across varying trials, real world data sources, and study design elements to better understand under what conditions non-interventional studies, using data generated during routine clinical care, can provide reliable conclusions about drug effectiveness. In this study, real-world electronic health record (EHR) data will be used to emulate the KEYNOTE-189 efficacy trial of pembrolizumab as first-line therapy in patients with metastatic non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) sensitizing mutations. Similarly to the KEYNOTE-189 trial, this study will compare real-world overall survival (rwOS) and real-world progression-free survival (rwPFS) between patients who initiate pemetrexed, platinum-based chemotherapy, and pembrolizumab, and patients who initiate pemetrexed and platinum-based chemotherapy alone.

Study Type

OBSERVATIONAL

Enrollment

851

Conditions

Metastatic Nonsmall Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-small cell lung cancer (NSCLC) diagnosis * Histology not indicative of squamous cell carcinoma * Metastatic disease * Epidermal growth factor receptor (EGFR) and Anaplastic lymphoma kinase (ALK)-negative or Kirsten rat sarcoma viral oncogene homolog (KRAS)-positive * No prior systemic treatment for metastatic NSCLC * No record of adjuvant or neoadjuvant therapy in the 12 months before metastatic diagnosis * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or missing or Karnofsky performance status \>=70 or missing * No lab results indicating inadequate organ function, as defined in the KEYNOTE-189 RCT protocol Exclusion Criteria: * Histology indicative of squamous cell carcinoma or small cell elements * Prior systemic treatment for metastatic NSCLC * Prior antineoplastic biological therapy * History of major cancer-related surgery in the 3 weeks before study drug initiation * Radiation therapy to the lung \>30 Gy in the 6 months before study drug initiation * Prior diagnosis of clinically active diverticulitis, intra-abdominal abscess, or gastrointestinal obstruction * Diagnosis of a second primary malignant neoplasm * Diagnosis of brain, central nervous system, and/or spinal cord metastases * Diagnosis of autoimmune disease and treatment with corticosteroids or immunosuppressive drugs after diagnosis and within the 2 years prior to study drug initiation * Treatment with a non-topical systemic steroid in each of the 6 months prior to study drug initiation * Prior treatment with pembrolizumab or any other anti-PD-1, PD-L1, PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms * Treatment with non-topical antibiotics, antifungals, or antivirals within 2 weeks after an infection diagnosis in the month prior to study drug initiation * Diagnosis of human immunodeficiency virus infection * Diagnosis of acute hepatitis B or C * Diagnosis of ascites or plural effusion in the 3 months prior to study drug initiation * Prior diagnosis of interstitial lung disease or diagnosis of pneumonitis and record of treatment with glucocorticoids within 30 days

Outcomes

Primary Outcomes

Real-world overall survival (rwOS)

Time from study treatment initiation to death

Time frame: From study treatment initiation until the date of death from any cause or censoring, whichever came first, assessed up to 20.4 months.

Real-world progression-free survival (rwPFS)

Time from study treatment initiation to disease progression or death

Time frame: From study treatment initiation until the date of disease progression, death from any cause or censoring, whichever came first, assessed up to 20.4 months.